Biolinq Incorporated, a US-based medtech company that is developing novel biosensing technologies, has signed an exclusive license agreement with Taisho Pharmaceutical Co, to commercialise a new generation of glucose monitoring products in Japan.

Under the agreement, the companies will collaborate to obtain regulatory approval for intradermal glucose sensing products in one of the largest medical device markets in the world. As the leading OTC pharmaceutical company in Japan, Taisho’s brand recognition and commercial reach covers a large majority of the health clinics that provide care for people with diabetes.

Biolinq’s patented technologies include a wearable sensor that uses an array of microneedles to measure glucose levels from the intradermal space just beneath the surface of the skin, and an integrated user interface that provides real-time feedback.

The Biolinq Sensor is an investigational device that is not yet cleared or approved by the FDA.